AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02052024
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
Trial: NCT02052024
Drug: MYOBLOC
RxNorm normalized name: Myobloc
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
Trial: NCT02159131
Drug: Ethinyl Estadiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Trial: NCT02159131
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
Trial: NCT00274261
Drug: C31G
RxNorm normalized name: C31G
DrugBank: C31G (DB05398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
Trial: NCT00620945
Drug: Phenoxybenzamine
RxNorm normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group
Trial: NCT02092298
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
Trial: NCT02092298
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
Trial: NCT02092298
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
Trial: NCT01711762
Drug: GDC-0973
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of \[14C\]-GDC-0973
Trial: NCT02570789
Drug: patients with sunitinib or pazopanib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
Trial: NCT03974867
Drug: Prednisone 5Mg Tab
RxNorm normalized name: PREDNISONE 5MG TAB
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;
Trial: NCT03247790
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03974867
Drug: Methylprednisolone 40 mg
RxNorm normalized name: methylprednisolone 40 MG
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;
Trial: NCT01332344
Drug: Fluticasone propionate/salmeterol combination
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
Trial: NCT00660517
Drug: azelastine Hcl
RxNorm normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: azelastine Hcl nasal spray one spray per nostril two times a day
Trial: NCT00660517
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
Trial: NCT00063726
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04299880
Drug: Napabucasin
RxNorm normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04299880
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT04299880
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT00519116
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00519116
Drug: Perioperative Corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The corticosteroids use was left up to the investigators decision.
Trial: NCT00671112
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.
Trial: NCT00671112
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
Trial: NCT04299880
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT04299880
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT04299880
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT04299880
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT00526630
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
Trial: NCT02001311
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04469595
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
Trial: NCT02208843
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib tablet once daily until progression
Trial: NCT01422213
Drug: Vortioxetine (Lu AA21004)
RxNorm normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: encapsulated tablets; daily; orally
Trial: NCT00180882
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02547012
Drug: esomeprazole+amox+levo+tetra
RxNorm normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Trial: NCT02547012
Drug: esomeprazole+amox+levo
RxNorm normalized name: esomeprazole, amoxicillin and clarithromycin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Trial: NCT01197534
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fostamatinib 100 mg twice daily
Trial: NCT01197534
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fostamatinib 100 mg twice daily/ 150 mg once daily
Trial: NCT01197534
Drug: placebo, fostamatinib
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
Trial: NCT01862978
Drug: Nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02092870
Drug: Adipose derived stem cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCs harvested from autologous lipoaspirate
Trial: NCT01355588
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg Ketorolac Tromethamine intranasal (IN)
Trial: NCT00484003
Drug: Pimecrolimus cream 1%
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01313078
Drug: Pegylated L-Asparaginase
RxNorm normalized name: Pegylated dickeya chrysanthemi l-asparaginase
DrugBank: Pegcrisantaspase (DB16281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
Trial: NCT01757587
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 50 mg, 2 tablets/day on 3 months, both periods of treatment
Trial: NCT00190645
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00537680
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
Trial: NCT00537680
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
Trial: NCT01482468
Drug: continuous infusion of palonosetron added to prophylactic single injection of palonosetron
RxNorm normalized name: palonosetron Injection
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
Trial: NCT01482468
Drug: continuous infusion of normal saline added to prophylactic single injection of palonosetron
RxNorm normalized name: varenicline
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: continuous infusion of normal saline after single injection of palonosetron 0.075mg
Trial: NCT01068717
Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Trial: NCT01068717
Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
Trial: NCT01068717
Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
Trial: NCT01068717
Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
Trial: NCT00179517
Drug: Anastrozole 1mg
RxNorm normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03490019
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500, 850 or 1000 mg depending on body weight once daily for 24 weeks
Trial: NCT02641093
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
Trial: NCT02641093
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
Trial: NCT02858804
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2, IV d1-4
Trial: NCT02858804
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/d, d1-5
Trial: NCT02858804
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/m2, IV, d1-4
Trial: NCT02858804
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2g/m2, q12h, d1
Trial: NCT02858804
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/ m2,IV, d1
Trial: NCT02858804
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV, d1
Trial: NCT02858804
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50-150mg/d, po, d1-28
Trial: NCT02858804
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/Kg, po, qod
Trial: NCT02583451
Drug: Placebo tablet matching lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet form taken orally at bedtime.
Trial: NCT02583451
Drug: Placebo tablet matching zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet form taken orally at bedtime.
Trial: NCT02583451
Drug: Zopiclone 7.5 mg
RxNorm normalized name: zopiclone 7.5 MG
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 mg tablet taken orally at bedtime.
Trial: NCT02583451
Drug: Lemborexant 2.5 mg
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 tablet taken orally at bedtime.
Trial: NCT02583451
Drug: Lemborexant 5 mg
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg tablet taken orally at bedtime.
Trial: NCT02583451
Drug: Lemborexant 10 mg
RxNorm normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet taken orally at bedtime.
Trial: NCT02198170
Drug: ketoconazole-placebo
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
Trial: NCT02198170
Drug: placebo-ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
Trial: NCT02731430
Drug: intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Trial: NCT02120118
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg/m2
Trial: NCT02120118
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2
Trial: NCT02174627
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Trial: NCT03517540
Drug: Tropifexor (LJN452)
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with monotherapy and different combination doses
Trial: NCT03517540
Drug: Cenicriviroc (CVC)
RxNorm normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with monotherapy and different combination doses
Trial: NCT02036073
Drug: recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
Trial: NCT04306731
Drug: Trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT03726372
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
Trial: NCT03858972
Drug: Tesetaxel
RxNorm normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesetaxel plus reduced dose of capecitabine
Trial: NCT01294241
Drug: Oleogel-S10
RxNorm normalized name: Oleogel-S10
DrugBank: Birch bark extract (DB16536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
Trial: NCT04321746
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
Trial: NCT03450317
Drug: Aspirin 80mg
RxNorm normalized name: Walgreens Infants' Non-Aspirin 80mg/0.8ml Drops (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No treatment
Trial: NCT01875523
Drug: Serelaxin
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00564850
Drug: Triptorelin pamoate 11.25mg (Decapeptyl® SR)
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One intra muscular injection at day 1 and month 3.
Trial: NCT04653038
Drug: MGD013
RxNorm normalized name: MGD013 dual-affinity re-targeting (DART)
DrugBank: Tebotelimab (DB16685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
Trial: NCT00677521
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
Trial: NCT00605618
Drug: BMS-777607
RxNorm normalized name: BMS-777607
DrugBank: BMS-777607 (DB12064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation